公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2015 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer | Chen J.S.; CHIH-HUNG HSU ; Chiang N.J.; Tsai C.S.; Tsou H.H.; Huang S.F.; Bai L.Y.; Chang I.C.; Shiah H.S.; Ho C.L.; Yen C.J.; Lee K.D.; Chiu C.F.; Rau K.M.; Yu M.S.; Yang Y.; Hsieh R.K.; Chang J.Y.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Wei T.-C.; on behalf of the Taiwan Cooperative Oncology Group | Annals of Oncology | 131 | 115 | |
2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | SUNG-HSIN KUO ; CHIH-HUNG HSU ; Chen L.-T.; YEN-SHEN LU ; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH ; ANN-LII CHENG | European Journal of Cancer | 17 | 17 | |
2021 | Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study | Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG ; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. | Therapeutic Advances in Medical Oncology | 3 | 5 | |
2008 | Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: Need for a revisit of surgical treatment | SUNG-HSIN KUO ; Chen L.-T.; MING-SHIANG WU ; CHUNG-WU LIN ; KUN-HUEI YEH ; KUAN-TING KUO ; Yeh P.-Y.; Tzeng Y.-S.; HSIU-PO WANG ; PING-NING HSU ; Lin J.-T.; ANN-LII CHENG | Annals of Surgery | 14 | 13 | |
2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; YEN-SHEN LU ; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN | World Journal of Gastroenterology | 18 | 14 | |
2012 | Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection | Chen L.-T.; Chen M.-F.; Li L.-A.; PO-HUANG LEE ; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; PEI-JER CHEN | Annals of Surgery | 111 | 106 | |
2005 | Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma | Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; HSIU-PO WANG ; SUNG-HSIN KUO ; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; ANN-LII CHENG | Journal of the National Cancer Institute | 173 | 135 | |
2003 | Low-dose thalidomide treatment for advanced hepatocellular carcinoma | CHIUN HSU ; CHIUNG-NIEN CHEN ; Chen L.-T.; Wu C.-Y.; PEI-MING YANG ; Lai M.-Y.; PO-HUANG LEE ; ANN-LII CHENG | Oncology | 87 | 77 | |
2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
2013 | Management of gastric cancer in Asia: Resource-stratified guidelines | Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH ; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. | The Lancet Oncology | 403 | 263 | |
1997 | Menadione-induced cytotoxicity to rat osteoblasts | JUI-SHENG SUN ; Tsuang Y.-H.; Huang W.-C.; Chen L.-T.; Hang Y.-S.; Lu F.-J. | Cellular and Molecular Life Sciences | 36 | 33 | |
2020 | A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue | Tsai H.-J.; Tai J.J.; Chen L.-T.; MING-SHIANG WU ; KUN-HUEI YEH ; CHUNG-WU LIN ; Wang T.-E.; HSIU-PO WANG ; Yu F.-J.; JYH-MING LIOU ; Hsiao C.-F.; TSU-YAO CHENG ; Yeh H.-J.; Ko C.-W.; Chen M.-J.; Lo G.-H.; Hsu P.-I.; Chang C.-S.; Hwang W.-S.; Chuang S.-S.; Lee H.-W.; CHIA-TUNG SHUN ; Chiu C.-F.; Wang W.-M.; Hsieh C.-Y.; Liu T.-W.; Lin J.-T.; SUNG-HSIN KUO ; ANN-LII CHENG | Haematologica | 5 | 5 | |
2020 | A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study | Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG ; Hsiao H.-H.; Shen W.-C.; CHIUN HSU ; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | European Journal of Cancer | 9 | 9 | |
2020 | Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study | Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG ; CHIUN HSU ; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | Liver International | 6 | 5 | |
2021 | The multiple mediating effects of cancer threat appraisal and quality of life on the association between mindfulness and depression for colorectal cancer survivors | Chen L.-T.; Cheng C.-T.; Huang I.-P.; Chang J.-H.; NIEN-TZU CHANG ; FEI-HSIU HSIAO | Psycho-Oncology | 3 | 3 | |
2016 | Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells | Cho C.-Y.; Huang J.-S.; Shiah S.-G.; Chung S.-Y.; Lay J.-D.; Yang Y.-Y.; Lai G.-M.; ANN-LII CHENG ; Chen L.-T.; Chuang S.-E. | RNA | 33 | 32 | |
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1656 | 1458 | |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 50 | 43 | |
2013 | No evidence of IGH-MALT1-translocation in the Ma-1 cell line-A reply | SUNG-HSIN KUO ; Weng W.-H.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 1 | 1 | |
2019 | Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma | SUNG-HSIN KUO ; MING-SHIANG WU ; KUN-HUEI YEH ; CHUNG-WU LIN ; PING-NING HSU ; Chen L.-T.; ANN-LII CHENG | Cancers | 21 | 22 | |